Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 3851–3900 of 18625
each of Hardeep Gulati, Laurence Goldberg, Maneet S. Saroya, Betty Hung, Gwen Reinke, Zach Levitt, Judy Cotte, Amy McIntosh, Barbara Byrne and Ronald D. McCray resigned from the Board of Directors
On October 1, 2024, the Board of Directors (the “Board”) of LPL Financial Holdings Inc. (the “Company”) terminated Dan H. Arnold, President and Chief Executive Officer of the Company, in the course of an investigation conducted by outside counsel that determined that Mr. Arnold made statements to employees that violated the Company’s Code of Conduct.
The Company also announced that Rich Steinmeier, currently the Managing Director, Chief Growth Officer of LPL Financial LLC, a subsidiary of the Company (“LPL Financial”), has been appointed as the Company’s Interim Chief Executive Officer, effective immediately.
On September 30, 2024, Verde Clean Fuels, Inc. (the “Company”) appointed George W. Burdette III (“Mr. Burdette”) as Chief Financial Officer of the Company
the Board announced that it had appointed (i) Mr. Frates to serve as the Company’s Executive Vice President and Chief Financial Officer, effective October 21, 2024
On September 25, 2024, the board of directors (the “ Board ”) of Windtree Therapeutics, Inc. (the “ Company ”) appointed Jamie McAndrew as Senior Vice President and Chief Financial Officer, effective as of September 25, 2024 (the “ Effective Date ”).
Ryan Barretto was appointed as Chief Executive Officer of the Company, effective October 1, 2024
On September 30, 2024, the Board of Directors (the “Board”) of BrightSphere Investment Group Inc. (the “Company”) appointed Kelly Young as the Company’s President and Chief Executive Officer and as a Director of the Company, each effective as of January 1, 2025.
On September 25, 2024, Jeff J. Kaminski notified KB Home of his intention to retire as Executive Vice President and Chief Financial Officer in early 2025, after more than 14 years of service.
On September 30, 2024, Vor Biopharma Inc. (the “Company”) announced that the board of directors (the “Board”) has appointed Han Choi, M.D., LL.M., as Chief Financial Officer of the Company, effective as of September 30, 2024 (the “Effective Date”).
Ms. Rexroad will succeed Robert Bowers in his role as Executive Vice President & Chief Financial & Administrative Officer.
The board of directors of Piedmont Office Realty Trust, Inc. (the “Company”) has appointed Sherry Rexroad as Chief Financial Officer of the Company, effective November 8, 2024.
the board of managers of the Company (the “Board”) has appointed Ms. Gloria Nelund, the Company’s Chief Executive Officer and President, to also temporarily serve as the Company’s interim Chief Financial Officer.
Mark A. Tipton resigned from his position as Chief Financial Officer of TriLinc Global Impact Fund, LLC
On September 25, 2024, the board of directors (the “ Board ”) of Lazydays Holdings, Inc., a Delaware corporation (the “ Company ”), appointed Jeff Huddleston, age 50, as Interim Chief Financial Officer of the Company.
On September 25, 2024, Ann C. Beemish, the Chief Financial Officer of MediaCo Holding Inc. (the “Company”), resigned as an officer of the Company, effective September 30, 2024.
On September 26, 2024, the Board of Directors (the “Board”) of the Company appointed Debra DeFelice, age 55, as the Company’s Chief Financial Officer and Treasurer.
On September 27, 2024, the Board of Directors of the Company announced the appointment of Jeffrey Royal as the Chief Executive Officer of the Company.
On September 27, 2024, Michael Rost departed as Chief Executive Officer of Nicholas Financial, Inc. (the “Company”).
On September 26, 2024, the Board appointed Tara Comonte as Interim President and Chief Executive Officer, effective September 27, 2024, to serve until a permanent President and Chief Executive Officer is identified.
On September 26, 2024, WW International, Inc. (the “Company”) and Sima Sistani, the Company’s President and Chief Executive Officer, mutually agreed that Ms. Sistani would cease serving as the Company’s President and Chief Executive Officer, effective September 27, 2024.
On September 25, 2024, the Board of Directors of the Company (the “Board”) designated Amy Elazzouzi, the Company’s Vice President, Finance, as the Company’s interim principal financial officer and interim principal accounting officer, in each case, effective on the Transition Date, to serve in such roles during the pendency of the Company’s search for a new Chief Financial Officer.
On September 23, 2024, Julie Feder notified Aura Biosciences, Inc. (the “Company”) of her departure from her role at the Company as an employee and Chief Financial Officer, effective as of October 25, 2024 (the “Transition Date”).
On September 23, 2024, Terence Kohler, Chief Financial Officer of the Company, notified the Company of his resignation from his position, effective October 4, 2024 (the “Separation Date”), to pursue a new business opportunity.
the Board appointed Bradley G. Smith as the Company’s Chief Financial Officer and designated him an executive officer of the Company, effective September 29, 2024.
Mr. Lahanas will resign as the Company’s Chief Financial Officer effective September 28, 2024.
the Board appointed Nicholas Lahanas as the Company’s Chief Executive Officer and a member of the Board effective September 29, 2024.
Charles A. Reinhart, III, the Company’s Chief Financial Officer, agreed that he would depart the Company effective September 30, 2024, and will continue to serve as consultant to the Company for a period of nine months thereafter.
On September 26, 2024, the Board of Directors of the Company (the “Board”) appointed Lauren Riker, the Company’s current Senior Vice President of Finance and principal accounting officer, to also serve as interim Chief Financial Officer of the Company (including as principal financial officer and continuing as principal accounting officer for Securities and Exchange Commission reporting purposes), effective October 1, 2024.
On September 23, 2024, Caribou Biosciences, Inc. (the “Company”) designated Ryan Fischesser, the Company’s current Vice President of Finance and Controller, as the Company’s interim principal financial officer and interim principal accounting officer, effective as of 5:00 p.m. Pacific time on September 27, 2024.
Mr. O’Byrne serves as the Company’s principal financial officer and principal accounting officer through September 27, 2024, his final day with the Company.
the Board of Directors of the Company (the “Board”) has appointed Jim Mintern to become the Company’s Chief Executive Officer, effective January 1, 2025.
Albert Manifold will retire from his position as Chief Executive Officer and as a member of the Board, effective December 31, 2024.
appointed Brad Garner as Chief Financial Officer, Matthew Lesmeister as Chief Operating Officer and Michael Guina as Chief Commercial Officer
Huang Hua Shang was appointed as Chief Executive Officer, Chief Financial Officer, Secretary and sole Director
On September 26. 2024, the Board of Directors of the registrant terminated Mr. Joseph Riccelli as the registrant’s Chief Executive Officer and Chief Financial Officer effective immediately.
On the same date the Board of Directors appointed John L. Thomas, Esq as the registrant’s Chief Executor Officer, Chief Financial Officer and corporate counsel.
On September 26, 2024, the Century Therapeutics, Inc. (the “Company”) announced the appointment of Morgan Conn, Ph.D. to serve as the Company’s Chief Financial Officer, effective October 14, 2024 (the “Effective Date”).
Mr. Christopher Lotz, Chief Financial Officer of the Company, also tendered his resignation from all positions held with the Company, with such resignation becoming effective immediately.
Mr. Michael Poirier, Chief Executive Officer and Chairman of the board of directors of Qualigen Therapeutics, Inc. (the “Company”), tendered his resignation from all positions held with the Company, with such resignation becoming effective immediately.
On September 25, 2024, the Boards of Directors of the Company and the Bank voted to extend Mr. Quinn’s retirement date to May 25, 2026 and Mr. Quinn accepted this extension.
The same day, Mr. Joe Kiani delivered a notification (the “ Notice ”) to the Board of Directors (the “ Board ”) of the Company stating his decision to resign from his position of Chief Executive Officer of the Company.
On September 24, 2024, the Board appointed Board member Michelle Brennan to serve as the Company’s interim chief executive officer (“ Interim CEO ”) effective immediately.
On September 20, 2024, Ms. Elisabeth A. Eden announced her intention to retire as Senior Vice President and Chief Financial Officer of TXNM Energy, Inc., a New Mexico corporation (“TXNM”), effective as of a date that is mutually agreeable between Ms. Eden and TXNM after a suitable successor is identified, currently anticipated to be no sooner than March 15, 2025 (the “Effective Date”).
Chris Ehrlich, the Vice Chairman of the Board, agreed to serve as Interim Chairman and Chief Executive Officer while the Board searches for a permanent replacement.
On September 22, 2024, the Company’s Chairman and Chief Executive Officer, Brian G. Atwood, informed the Board of his resignation as Chief Executive Officer, effective at a date to be determined, which shall be no later than September 30, 2024.
the Board of Directors (the " Board ") of Thermon Group Holdings, Inc. (the “ Company ”) appointed Jan L. Schott as the Company’s Senior Vice President and Chief Financial Officer, effective October 14, 2024.
the Board appointed Jamie Pirrello, a current member of the Board and a consultant to the Company, as interim Chief Executive Officer of the Company.
On September 20, 2024, the Board appointed Dr. Cornelius Boersch to serve in the role of interim Chief Financial Officer until a permanent replacement is found.
the Board has appointed Werner Schwock to serve as the Company’s Interim Chief Financial Officer and function as the principal financial and accounting officer for the Company.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.